Buprenorphine/naloxone
Buprenorphine/naloxone (trade name Suboxone) is a combination drug formulation of buprenorphine, a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor antagonist, and naloxone, a MOR silent antagonist, in a 4:1 ratio. It is used in the treatment of opioid dependence. The purpose of naloxone is to deter intravenous abuse; parenteral administration rapidly induces opioid withdrawal symptoms, while regular, intended use does not (as naloxone is minimally bioavailable with sublingual ingestion). In spite of the fact that the drug is intended to treat opioid dependence, it is still addictive.
Buprenorphine/naloxone
Buprenorphine/naloxone (trade name Suboxone) is a combination drug formulation of buprenorphine, a μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor antagonist, and naloxone, a MOR silent antagonist, in a 4:1 ratio. It is used in the treatment of opioid dependence. The purpose of naloxone is to deter intravenous abuse; parenteral administration rapidly induces opioid withdrawal symptoms, while regular, intended use does not (as naloxone is minimally bioavailable with sublingual ingestion). In spite of the fact that the drug is intended to treat opioid dependence, it is still addictive.
has abstract
Buprenorphine/naloxone (trade ...... as sublingual tablets or film.
@en
ATC prefix
ATC suffix
PubChem
Wikipage page ID
43,393,518
Wikipage revision ID
743,578,432
component
legal US
routes of administration
tradename
Suboxone, Bunavail, Zubsolv
subject
hypernym
comment
Buprenorphine/naloxone (trade ...... ndence, it is still addictive.
@en
label
Buprenorphine/naloxone
@en